Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Role of genomic factors beyond thymidylate synthase in the prediction of response to 5-fluorouracil.

Peters GJ, Smid K, Meijer E, van Groeningen CJ, Leon LG.

Nucleosides Nucleotides Nucleic Acids. 2016 Dec;35(10-12):595-603.

PMID:
27906628
2.

The Cytidine Analog Fluorocyclopentenylcytosine (RX-3117) Is Activated by Uridine-Cytidine Kinase 2.

Sarkisjan D, Julsing JR, Smid K, de Klerk D, van Kuilenburg AB, Meinsma R, Lee YB, Kim DJ, Peters GJ.

PLoS One. 2016 Sep 9;11(9):e0162901. doi: 10.1371/journal.pone.0162901. eCollection 2016.

3.

A red-shifted photochromic sulfonylurea for the remote control of pancreatic beta cell function.

Broichhagen J, Frank JA, Johnston NR, Mitchell RK, Šmid K, Marchetti P, Bugliani M, Rutter GA, Trauner D, Hodson DJ.

Chem Commun (Camb). 2015 Apr 7;51(27):6018-21. doi: 10.1039/c5cc01224d. Epub 2015 Mar 11.

PMID:
25744824
4.

Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine.

Adema AD, Floor K, Smid K, Honeywell RJ, Scheffer GL, Jansen G, Peters GJ.

Springerplus. 2014 Dec 13;3:732. doi: 10.1186/2193-1801-3-732. eCollection 2014.

5.

Inhibition of thymidylate synthase by 2',2'-difluoro-2'-deoxycytidine (Gemcitabine) and its metabolite 2',2'-difluoro-2'-deoxyuridine.

Honeywell RJ, Ruiz van Haperen VW, Veerman G, Smid K, Peters GJ.

Int J Biochem Cell Biol. 2015 Mar;60:73-81. doi: 10.1016/j.biocel.2014.12.010. Epub 2015 Jan 3.

PMID:
25562513
6.

A novel cytidine analog, RX-3117, shows potent efficacy in xenograft models, even in tumors that are resistant to gemcitabine.

Yang MY, Lee YB, Ahn CH, Kaye J, Fine T, Kashi R, Ohne O, Smid K, Peters GJ, Kim DJ.

Anticancer Res. 2014 Dec;34(12):6951-9.

PMID:
25503121
7.

Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia.

Maftouh M, Avan A, Sciarrillo R, Granchi C, Leon LG, Rani R, Funel N, Smid K, Honeywell R, Boggi U, Minutolo F, Peters GJ, Giovannetti E.

Br J Cancer. 2014 Jan 7;110(1):172-82. doi: 10.1038/bjc.2013.681. Epub 2013 Oct 31.

8.

Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360).

Peters GJ, Smid K, Vecchi L, Kathmann I, Sarkisjan D, Honeywell RJ, Losekoot N, Ohne O, Orbach A, Blaugrund E, Jeong LS, Lee YB, Ahn CH, Kim DJ.

Invest New Drugs. 2013 Dec;31(6):1444-57. doi: 10.1007/s10637-013-0025-x. Epub 2013 Sep 19.

PMID:
24048768
9.

The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: results from a prospective pharmacological study.

Seinen ML, van Asseldonk DP, de Boer NK, Losekoot N, Smid K, Mulder CJ, Bouma G, Peters GJ, van Bodegraven AA.

J Crohns Colitis. 2013 Nov;7(10):812-9. doi: 10.1016/j.crohns.2012.12.006. Epub 2013 Jan 11.

PMID:
23317929
10.

Why you need to look where you step for precise foot placement: the effects of gaze eccentricity on stepping errors.

Smid KA, den Otter AR.

Gait Posture. 2013 Jun;38(2):242-6. doi: 10.1016/j.gaitpost.2012.11.019. Epub 2012 Dec 21.

PMID:
23266044
11.

Allopurinol enhances the activity of hypoxanthine-guanine phosphoribosyltransferase in inflammatory bowel disease patients during low-dose thiopurine therapy: preliminary data of an ongoing series.

Seinen ML, de Boer NK, Smid K, van Asseldonk DP, Bouma G, van Bodegraven AA, Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2011 Dec;30(12):1085-90. doi: 10.1080/15257770.2011.597371.

PMID:
22132961
12.

Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126.

Adema AD, Smid K, Losekoot N, Honeywell RJ, Verheul HM, Myhren F, Sandvold ML, Peters GJ.

Invest New Drugs. 2012 Oct;30(5):1908-16. doi: 10.1007/s10637-011-9756-8. Epub 2011 Oct 15.

13.

Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.

Giovannetti E, Zucali PA, Assaraf YG, Leon LG, Smid K, Alecci C, Giancola F, Destro A, Gianoncelli L, Lorenzi E, Roncalli M, Santoro A, Peters GJ.

Br J Cancer. 2011 Nov 8;105(10):1542-53. doi: 10.1038/bjc.2011.400. Epub 2011 Oct 4.

14.

DNA copy number profiles correlate with outcome in colorectal cancer patients treated with fluoropyrimidine/antifolate-based regimens.

Leon LG, Giovannetti E, Smid K, van Houte BP, Hanauske AR, Giaccone G, Peters GJ.

Curr Drug Metab. 2011 Dec;12(10):956-65. Review.

PMID:
21787269
15.

Biotransformation of 6-thioguanine in inflammatory bowel disease patients: a comparison of oral and intravenous administration of 6-thioguanine.

Jharap B, de Boer N, Vos R, Smid K, Zwiers A, Peters G, Mulder C, Wilhelm A, van Bodegraven A.

Br J Pharmacol. 2011 Jun;163(4):722-31. doi: 10.1111/j.1476-5381.2011.01265.x.

16.

Induction of resistance to the lipophilic cytarabine prodrug elacytarabine (CP-4055) in CEM leukemic cells.

Adema AD, Losekoot N, Smid K, Kathmann I, Myhren F, Sandvold ML, Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2010 Jun;29(4-6):394-9. doi: 10.1080/15257771003741166.

PMID:
20544525
17.

Limited intra-individual variability in hypoxanthine-Guanine phosphoribosyl transferase, thiopurine S-methyl transferase, and xanthine oxidase activity in inflammatory bowel disease patients during 6-thioguanine therapy.

van Asseldonk DP, de Boer NK, Smid K, Mulder CJ, van Bodegraven AA, Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2010 Jun;29(4-6):284-90. doi: 10.1080/15257771003730052.

PMID:
20544508
18.

Trifluorothymidine resistance is associated with decreased thymidine kinase and equilibrative nucleoside transporter expression or increased secretory phospholipase A2.

Temmink OH, Bijnsdorp IV, Prins HJ, Losekoot N, Adema AD, Smid K, Honeywell RJ, Ylstra B, Eijk PP, Fukushima M, Peters GJ.

Mol Cancer Ther. 2010 Apr;9(4):1047-57. doi: 10.1158/1535-7163.MCT-09-0932. Epub 2010 Apr 6.

19.

Cellular pharmacology of multi- and duplex drugs consisting of ethynylcytidine and 5-fluoro-2'-deoxyuridine.

Bijnsdorp IV, Schwendener RA, Schott H, Fichtner I, Smid K, Laan AC, Schott S, Losekoot N, Honeywell RJ, Peters GJ.

Invest New Drugs. 2011 Apr;29(2):248-57. doi: 10.1007/s10637-009-9353-2. Epub 2009 Dec 3.

20.

Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines.

Bijnsdorp IV, Kruyt FA, Fukushima M, Smid K, Gokoel S, Peters GJ.

Cancer Sci. 2010 Feb;101(2):440-7. doi: 10.1111/j.1349-7006.2009.01375.x. Epub 2009 Sep 29.

21.

Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer.

Mauritz R, Giovannetti E, Beumer IJ, Smid K, Van Groeningen CJ, Pinedo HM, Peters GJ.

Clin Colorectal Cancer. 2009 Jul;8(3):146-54. doi: 10.3816/CCC.2009.n.024.

PMID:
19632929
22.

Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells.

Tekle C, Giovannetti E, Sigmond J, Graff JR, Smid K, Peters GJ.

Br J Cancer. 2008 Sep 2;99(5):750-9. doi: 10.1038/sj.bjc.6604566. Epub 2008 Aug 19.

23.

Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.

Giovannetti E, Lemos C, Tekle C, Smid K, Nannizzi S, Rodriguez JA, Ricciardi S, Danesi R, Giaccone G, Peters GJ.

Mol Pharmacol. 2008 Apr;73(4):1290-300. doi: 10.1124/mol.107.042382. Epub 2008 Jan 10.

24.

In vivo and in vitro activity and mechanism of action of the multidrug cytarabine-L-glycerylyl-fluorodeoxyuridine.

Bijnsdorp IV, Schwendener RA, Schott H, Fichtner I, Smid K, Schott S, Laan AC, Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2007;26(10-12):1619-24.

PMID:
18066839
25.

Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer.

Mauritz R, van Groeningen CJ, Smid K, Jansen G, Pinedo HM, Peters GJ.

Int J Cancer. 2007 Jun 15;120(12):2609-12.

26.

Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits.

Smid K, Bergman AM, Eijk PP, Veerman G, van Haperen VW, van den Ijssel P, Ylstra B, Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2006;25(9-11):1001-7.

PMID:
17065054
27.

Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.

Peters GJ, Van Moorsel CJ, Lakerveld B, Smid K, Noordhuis P, Comijn EC, Weaver D, Willey JC, Voorn D, Van der Vijgh WJ, Pinedo HM.

Int J Oncol. 2006 Jan;28(1):237-44.

PMID:
16328001
28.

Expression microarray analysis and oligo array comparative genomic hybridization of acquired gemcitabine resistance in mouse colon reveals selection for chromosomal aberrations.

van de Wiel MA, Costa JL, Smid K, Oudejans CB, Bergman AM, Meijer GA, Peters GJ, Ylstra B.

Cancer Res. 2005 Nov 15;65(22):10208-13.

29.

Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.

Smorenburg CH, Peters GJ, van Groeningen CJ, Noordhuis P, Smid K, van Riel AM, Dercksen W, Pinedo HM, Giaccone G.

Ann Oncol. 2006 Jan;17(1):35-42. Epub 2005 Oct 26.

PMID:
16251201
30.

In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant.

Bergman AM, Eijk PP, Ruiz van Haperen VW, Smid K, Veerman G, Hubeek I, van den Ijssel P, Ylstra B, Peters GJ.

Cancer Res. 2005 Oct 15;65(20):9510-6.

31.

Role of platelet derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity and potential role of deoxyribose-1-phosphate.

de Bruin M, van Capel T, Smid K, van der Born K, Fukushima M, Hoekman K, Pinedo HM, Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1485-90.

PMID:
15571282
32.

Comparison of mRNA expression levels determined with TaqMan and competitive template RT-PCR.

Mauritz R, Schwabe W, Haeusler P, Noordhuis P, Smid K, McLeod HL, Behnke D, van Groeningen CJ, Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1471-4.

PMID:
15571279
33.

Polymorphism of the thymidylate synthase gene and thymidylate synthase levels in colon cancer cell lines and different tissues of colorectal cancer patients.

Mauritz R, Beumer IJ, Marsh S, McLeod HL, Smid K, van Groeningen CJ, Pinedo HM, Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1381-4.

PMID:
15571263
34.

Upregulation of platelet derived endothelial cell growth factor/thymidine phosphorylase by interferon alpha.

de Bruin M, Smid K, van der Ent MA, Fukushima M, Pinedo HM, Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1367-70.

PMID:
15571260
35.

Antiproliferative activity and mechanism of action of fatty acid derivatives of gemcitabine in leukemia and solid tumor cell lines and in human xenografts.

Bergman AM, Kuiper CM, Noordhuis P, Smid K, Voorn DA, Comijn EM, Myhren F, Sandvold ML, Hendriks HR, Fodstad O, Breistøl K, Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1329-33.

PMID:
15571253
36.

5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers.

Noordhuis P, Holwerda U, Van der Wilt CL, Van Groeningen CJ, Smid K, Meijer S, Pinedo HM, Peters GJ.

Ann Oncol. 2004 Jul;15(7):1025-32.

PMID:
15205195
37.

The effect of fluoropyrimidines with or without thymidine phosphorylase inhibitor on the expression of thymidine phosphorylase.

De Bruin M, Van Capel T, Smid K, Fukushima M, Hoekman K, Pinedo HM, Peters GJ.

Eur J Pharmacol. 2004 May 3;491(2-3):93-9.

PMID:
15140625
38.

Hear ye hear ye: a comprehensive ear care program for residents residing in long-term care facilities.

Smid K, Short D.

Perspectives. 2003 Fall;27(3):3-4. No abstract available.

PMID:
14752944
39.

Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.

Peters GJ, Noordhuis P, Van Kuilenburg AB, Schornagel JH, Gall H, Turner SL, Swart MS, Voorn D, Van Gennip AH, Wanders J, Holwerda U, Smid K, Giaccone G, Fumoleau P, Van Groeningen CJ.

Cancer Chemother Pharmacol. 2003 Jul;52(1):1-12. Epub 2003 May 9.

PMID:
12739060
40.

Rapid disappearance of deoxyribose-1-phosphate in platelet derived endothelial cell growth factor/thymidine phosphorylase overexpressing cells.

de Bruin M, Smid K, Laan AC, Noordhuis P, Fukushima M, Hoekman K, Pinedo HM, Peters GJ.

Biochem Biophys Res Commun. 2003 Feb 14;301(3):675-9.

PMID:
12565833
41.

Effect of gemcitabine and cis-platinum combinations on ribonucleotide and deoxyribonucleotide pools in ovarian cancer cell lines.

Van Moorsel CJ, Smid K, Voorn DA, Bergman AM, Pinedo HM, Peters GJ.

Int J Oncol. 2003 Jan;22(1):201-7.

PMID:
12469205
42.

Effects of antifolates on the binding of 5-fluoro-2'-deoxyuridine monophosphate to thymidylate synthase.

van der Wilt CL, Smid K, Peters GJ.

Biochem Pharmacol. 2002 Aug 15;64(4):669-75.

PMID:
12167486
43.

High-dose 5-Fluorouracil with uridine-diphosphoglucose rescue increases thymidylate synthase inhibition but not 5-Fluorouracil incorporation into RNA in murine tumors.

Codacci-Pisanelli G, Van der Wilt CL, Smid K, Noordhuis P, Voorn D, Pinedo HM, Peters GJ.

Oncology. 2002;62(4):363-70.

PMID:
12138245
44.

Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism.

Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid K, Lunec J, Calvert AH, Marsh S, McLeod HL, Bloemena E, Meijer S, Jansen G, van Groeningen CJ, Pinedo HM.

Biochim Biophys Acta. 2002 Jul 18;1587(2-3):194-205. Review.

45.

Maintenance of ATP favours apoptosis over necrosis triggered by benzamide riboside.

Grusch M, Polgar D, Gfatter S, Leuhuber K, Huettenbrenner S, Leisser C, Fuhrmann G, Kassie F, Steinkellner H, Smid K, Peters GJ, Jayaram HN, Klepal W, Szekeres T, Knasmüller S, Krupitza G.

Cell Death Differ. 2002 Feb;9(2):169-78.

46.

Issues of normal tissue toxicity in patient and animal studies--effect of carbogen breathing in rats after 5-fluorouracil treatment.

Griffiths JR, McIntyre DJ, Howe FA, McSheehy PM, Ojugo ASE, Rodrigues LM, Wadsworth P, Price NM, Lofts F, Nicholson G, Smid K, Noordhuis P, Peters GJ, Stubbs M.

Acta Oncol. 2001;40(5):609-14.

PMID:
11669333
47.

Interference of gemcitabine triphosphate with the measurements of deoxynucleotides using an optimized DNA polymerase elongation assay.

Smid K, Van Moorsel CJ, Noordhuis P, Voorn DA, Peters GJ.

Int J Oncol. 2001 Jul;19(1):157-62.

PMID:
11408937
48.

Activation of caspases and induction of apoptosis by novel ribonucleotide reductase inhibitors amidox and didox.

Grusch M, Fritzer-Szekeres M, Fuhrmann G, Rosenberger G, Luxbacher C, Elford HL, Smid K, Peters GJ, Szekeres T, Krupitza G.

Exp Hematol. 2001 May;29(5):623-32.

PMID:
11376876
49.

Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.

Bergman AM, Munch-Petersen B, Jensen PB, Sehested M, Veerman G, Voorn DA, Smid K, Pinedo HM, Peters GJ.

Biochem Pharmacol. 2001 Jun 1;61(11):1401-8.

PMID:
11331076
50.

Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.

van der Wilt CL, Backus HH, Smid K, Comijn L, Veerman G, Wouters D, Voorn DA, Priest DG, Bunni MA, Mitchell F, Jackman AL, Jansen G, Peters GJ.

Cancer Res. 2001 May 1;61(9):3675-81.

Supplemental Content

Support Center